Published in Cancer Epidemiol Biomarkers Prev on May 01, 2011
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med (2014) 1.32
Expected population impacts of discontinued prostate-specific antigen screening. Cancer (2014) 1.24
Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. JAMA Oncol (2016) 1.04
Individualized estimates of overdiagnosis in screen-detected prostate cancer. J Natl Cancer Inst (2014) 1.04
Doctors' approaches to PSA testing and overdiagnosis in primary healthcare: a qualitative study. BMJ Open (2015) 1.03
Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol (2013) 1.00
Effects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trial. J Natl Cancer Inst (2013) 0.95
Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. Int J Cancer (2014) 0.94
Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer. Cancer Epidemiol Biomarkers Prev (2015) 0.88
Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy. Adv Urol (2012) 0.87
Elevated HERV-K mRNA expression in PBMC is associated with a prostate cancer diagnosis particularly in older men and smokers. Carcinogenesis (2014) 0.86
Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality. J Natl Cancer Inst Monogr (2013) 0.82
Semicompeting risks in aging research: methods, issues and needs. Lifetime Data Anal (2014) 0.81
Patented prostate cancer biomarkers. Nat Rev Urol (2012) 0.79
Elevated hyaluronan and hyaluronan-mediated motility receptor are associated with biochemical failure in patients with intermediate-grade prostate tumors. Cancer (2014) 0.78
High RhoA expression at the tumor front in clinically localized prostate cancer and association with poor tumor differentiation. Oncol Lett (2015) 0.78
Multilevel modeling and value of information in clinical trial decision support. BMC Syst Biol (2014) 0.75
Social network effects of nonlifesaving early-stage breast cancer detection on mammography rates. Am J Public Health (2014) 0.75
What are the consequences if i postpone treatment of my PSA-detected prostate cancer? Cancer Epidemiol Biomarkers Prev (2011) 0.75
Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence. Med Care (2013) 0.75
Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies. Am J Epidemiol (2016) 0.75
Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions. Eur Urol (2017) 0.75
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2005) 16.35
20-year outcomes following conservative management of clinically localized prostate cancer. JAMA (2005) 12.25
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (2003) 11.27
A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA (1995) 8.60
Natural history of early, localized prostate cancer. JAMA (2004) 7.44
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst (2009) 6.96
Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med (2008) 6.02
Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst (2005) 5.10
Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer (2008) 3.06
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2005) 3.01
Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control (2007) 2.69
A population model of prostate cancer incidence. Stat Med (2006) 2.44
Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst (1999) 2.35
Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer (2007) 2.31
Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics (2007) 2.09
Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making (2008) 2.06
Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam. J Natl Cancer Inst (2010) 1.83
Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol (1998) 1.68
A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer (2006) 1.65
Gleason score, age and screening: modeling dedifferentiation in prostate cancer. Int J Cancer (2006) 1.64
Survival prospects after screen-detection of prostate cancer. BJU Int (2002) 1.58
Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics (2010) 1.42
Combining longitudinal studies of PSA. Biostatistics (2004) 1.40
Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology (2002) 1.15
Stage-specific cancer incidence: an artificially mixed multinomial logit model. Stat Med (2009) 0.95
Predicting survival for men with clinically localized prostate cancer: what do we need in contemporary practice? Cancer (2008) 0.92
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (2003) 11.27
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst (2002) 9.45
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med (2004) 8.91
Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med (2013) 7.95
Quality-of-life effects of prostate-specific antigen screening. N Engl J Med (2012) 7.21
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst (2009) 6.96
Management of lung nodules detected by volume CT scanning. N Engl J Med (2009) 6.79
Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst (2004) 5.84
Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst (2005) 5.10
Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol (2011) 5.01
Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care (2002) 4.88
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med (2009) 4.60
Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med (2013) 4.45
Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet (2003) 4.20
Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst (2005) 4.01
Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst (2013) 3.81
Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med (2013) 3.74
Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial. Am J Respir Crit Care Med (2013) 3.47
Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med (2014) 3.46
A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res (2008) 3.35
Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter? J Urol (2012) 3.30
Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst (2010) 3.24
American Cancer Society lung cancer screening guidelines. CA Cancer J Clin (2013) 3.16
Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int (2012) 2.88
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer (2007) 2.85
Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med (2013) 2.77
Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control (2007) 2.69
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. J Clin Epidemiol (2011) 2.46
Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. Eur Urol (2013) 2.43
Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer (2006) 2.42
The association between diffusion of the surgical robot and radical prostatectomy rates. Med Care (2011) 2.38
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
Immediate effects of the initial FDA notification on the use of surgical mesh for pelvic organ prolapse surgery in medicare beneficiaries. Neurourol Urodyn (2012) 2.35
Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer (2007) 2.31
Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst (2014) 2.30
Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000. J Natl Cancer Inst (2012) 2.30
Continuous Bayesian adaptive randomization based on event times with covariates. Stat Med (2006) 2.30
Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol (2007) 2.24
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol (2005) 2.24
Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. Heart Rhythm (2013) 2.22
Studies of prostate-cancer mortality: caution advised. Lancet Oncol (2008) 2.22
Models in the development of clinical practice guidelines. Ann Intern Med (2014) 2.18
Access to information sources and treatment considerations among men with local stage prostate cancer. Urology (2009) 2.15
Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics (2007) 2.09
Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making (2008) 2.06
Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. Ann Intern Med (2012) 1.99
Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol (2005) 1.97
Identification of chronic obstructive pulmonary disease in lung cancer screening computed tomographic scans. JAMA (2011) 1.94
Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer (2005) 1.93
Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States. Cancer Epidemiol Biomarkers Prev (2010) 1.93
Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study. Ann Intern Med (2014) 1.87
Mammography screening and risk of breast cancer death: a population-based case-control study. Cancer Epidemiol Biomarkers Prev (2011) 1.85
Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. J Natl Cancer Inst (2008) 1.84
National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. J Urol (2012) 1.84
Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam. J Natl Cancer Inst (2010) 1.83
Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med (2003) 1.79
Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev (2011) 1.77
Volume outcomes of cystectomy--is it the surgeon or the setting? J Urol (2012) 1.77
Patients' perceptions of the side-effects of prostate cancer treatment--a qualitative interview study. Soc Sci Med (2006) 1.76
Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. J Gen Intern Med (2011) 1.76
Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. J Urol (2007) 1.74
Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. J Urol (2011) 1.72
Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology (2004) 1.71
Additional double reading of screening mammograms by radiologic technologists: impact on screening performance parameters. J Natl Cancer Inst (2007) 1.69
Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol (2004) 1.68
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res (2008) 1.68
Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol (2008) 1.66
It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer. J Urol (2008) 1.66
Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. Urology (2013) 1.66
Gleason score, age and screening: modeling dedifferentiation in prostate cancer. Int J Cancer (2006) 1.64